CRX.L Regulatory News (CRX)

28 January 2013

Cyprotex PLC

("Cyprotex" or "the Company")

Grant of Options

Further to the announcement made on 23 January, the Company announces today that Tony Baxter, Chief Executive Officer of the Company, has been granted 20,000,001 options, all over ordinary shares of 0.1p each as part of the executive share option scheme.

The vesting of these executive options is on grant, at an exercise price of 6 pence per share, and are exercisable only upon change of control of the Company within a ten year period, dependent upon the Company's share price performance and subject to a minimum share price of 12 pence.

-Ends-

About Cyprotex PLC 

Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotech's to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.